La cadena de opciones muestra datos clave de las opciones de acciones de HeartSciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para HeartSciences..

HeartSciences (NASDAQ:HSCS) Bolsa, Cadena de Opciones

Heart Test Laboratories

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

HeartSciences Inc

JFBR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

LUXH

JFBRW

LUXHP

"The days of retail being a fringe player are over," said Eric Krueger, CEO of GTN Americas at <a href="https://benzinga.swoogo.com/fintech-awards/6073689">Benzinga Fintech Deal Day</a>, during a panel called "Bridging Divides: Connecting Wall Street with Main Street.&#8221;
The panel, moderated by Brandis DeSimone, head of data sales at Nasdaq, brought together voices from Public.com, Alpaca, TradeZero and GTN to explore innovation, education and the global rise of retail trading.
See Also:<a href="https://www.benzinga.com/news/events/24/11/42072183/will-ai-become-an-assistant-or-a-master-experts-beg-to-differ-at-benzinga-fintech-conference"> Will AI Become An Assistant Or A Master? Experts Beg To Differ At Benzinga Fintech Conference</a> Reflecting on his early days at Merrill Lynch, Krueger described how trading has evolved from $100 commissions to instant, no-cost trades on a mobile app. "That friction is gone, and it's made retail a major force in the market."
But the increasing presence of retail investors raised questions about their readiness for sophisticated markets. 
On one side, Samuel Nofzinger, head of Brokerage and Crypto at Public.com, argued that learning through mistakes is essential. "We can't be too paternalistic," he said. "Guardrails are important, but you have to let people fail. That's how they grow from chasing meme stocks to building diversified portfolios."
Yoshi Yokokawa, CEO of Alpaca, offered a cautious counterpoint, warning about the dangers of pushing risk too far. "We've seen what happens when innovation outpaces responsibility, like during the crypto boom and bust," he said. 
Yokokawa, who worked at Lehman Brothers during the 2008 financial crisis, stressed that fintech companies have a duty to balance access with protection. "We have to ask: how much risk should we be introducing to the average investor?"
<h1 class="wp-block-heading">Innovation vs. Responsibility</h1>
One recurring theme was how to simplify complex financial products without oversimplifying their risks. Nofzinger pointed to Public's approach to fixed-income products as an example. 
"Bonds are complicated, but we've repackaged them into something retail investors understand: a yield-focused account," he said. The result was striking — on launch day, Public handled 8% of all U.S. bond trades.
"Offering a new product is great, but making it digestible is where the real work happens," Krueger noted. He warned against overwhelming retail users with overly complex choices. "Retail investors don't wake up thinking, ‘Let me buy some bonds.' They think, ‘Where can I get the best yield?' Simplifying that process is key."
Yokokawa agreed but remained wary of the long-term implications. "When you chase yield, you're pushing the limits," he said. "That's how boom-and-bust cycles happen. We have to remember that retail isn't just numbers — it's people's savings, their futures."
<h1 class="wp-block-heading">Striking A Balance: Education and Risk</h1>
Panelists debated the best approach to educating retail investors without stifling their autonomy. Nofzinger talked about meeting users where they are, including platforms such as TikTok and Meta Platform&#8217;s Instagram. "If you're not there, you're invisible to this generation of investors," he said.
Meanwhile, Daniel Pipitone, co-founder and CEO of TradeZero, focused on working with unbiased educators to teach strategies and risk management. He echoed Nofzinger's belief that mistakes are part of the process. "You can't control what people do, and they need room to learn. But platforms need to provide tools that help guide them responsibly."
Krueger added a different perspective, calling for education to be embedded directly into trading platforms. "It's not enough to have a help section buried in a menu. If someone is overtrading after a loss, we need to deliver advice right then and there," he said. "It's about personalization, not one-size-fits-all solutions."
<h1 class="wp-block-heading">Main Street Is Everywhere</h1>
Retail's expansion is not just a U.S. story — it's a global one. Pipitone described how demand for U.S. equities is booming abroad. "Main Street has expanded beyond borders," he said. "People everywhere want to trade Tesla or Nvidia because these brands are part of their lives."
Krueger noted that 90% of trading volumes for GTN's international partners are in U.S. markets, driven by the consistent outperformance of American stocks. 
Yet scaling globally isn't easy. "Serving smaller markets means you need incredibly low costs," Yokokawa explained. "That only works if you internalize every part of your operations, from technology to customer acquisition."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/events/24/11/42073346/exclusive-retail-investors-are-taking-on-more-risk-and-finding-success-is-crypto-acting-as-a-gateway-trade">EXCLUSIVE: Retail Investors Are Taking On More Risk And Finding Success — Is Crypto Acting As A &#8216;Gateway Trade?&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Retail Sales

Events

Exclusives

Personal Finance

EXCLUSIVE: Wall Street Meets Main Street — Fintech Experts Weigh In On Retail's Rise

Robert Mitchnick, head of digital assets at BlackRock, told a panel at the Benzinga <a href="https://www.benzinga.com/digital-assets">Future of Digital Assets </a>conference on Nov. 19 that options volume on the iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) breached the 1 billion <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42058823/blackrocks-spot-bitcoin-etf-to-open-for-options-trading-heres-why-it-could-be-a-big-deal-for-bitcoin">mark on Tuesday. </a>
"Things happen fast here," Mitchnick said. 
The Details: Nasdaq began listing options on BlackRock's spot Bitcoin ETF on Tuesday with 73,000 contracts traded in the first 90 minutes, ranking IBIT options among the top 20 most active non-index options. 
BlackRock's IBIT is currently the only spot Bitcoin ETF listed on Nasdaq, but competitors listed on the New York Stock Exchange (NYSE) and Cboe Global Markets are expected to launch similar options trading in the coming days.
Bloomberg senior ETF analyst Eric Balchunas noted that the volume was almost entirely calls, indicating a strong bullish sentiment in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A few hundred million so far in options volume on <a href="https://twitter.com/search?q=%24IBIT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$IBIT</a> (a ton for Day One).. here&#39;s a rank of the contracts by volume, it&#39;s almost all calls. Seems very bullish, esp the Dec20th C100, which is basically betting price of btc will double in the next month. <a href="https://t.co/R6HB7OMUla">pic.twitter.com/R6HB7OMUla</a>
&mdash; Eric Balchunas (@EricBalchunas) <a href="https://twitter.com/EricBalchunas/status/1858916477384225005?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42071163/blackrock-spot-bitcoin-etf-options-on-nasdaq-rack-up-9-figure-trading-volume-in-first-few-hours-seems-very-bullish-says-analyst">derivatives market </a>for traditional assets can often grow to be up to 20 times the size of the underlying asset&#8217;s market cap. If Bitcoin derivatives follow a similar trajectory, the listing of IBIT options could significantly expand the reach and functionality of Bitcoin-linked financial products.
"There's a ton of work to do to flesh out the investor opportunity and uptake around what we have," Mitchnick said. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: John Dave from Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Specialty ETFs

Options

Movers

ETFs

$BTC

IBIT

BlackRock's Head Of Digital Assets Says IBIT Spot Bitcoin ETF Options Blow Past 1 Billion In Trading Volume

Congressman Matt Gaetz (R-Fla.) resigned from office after he was announced as President-elect Donald Trump's pick<a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation"> for attorney general.</a>
While Gaetz has not been formally nominated for the White House role, his resignation could keep an investigation into his actions from being publicly released.
What Happened: Prior to<a href="https://www.benzinga.com/news/24/11/42024613/lawyer-ethics-committee-witness-says-she-saw-ag-nominee-gaetz-having-sex-with-a-minor"> resigning from Congress</a>, Gaetz was under investigation by the House Ethics Committee for allegations of sexual misconduct, drug use and more.
With Gaetz no longer a member of Congress, the Ethics Committee has no jurisdiction over him, but their decision of whether to release their findings publicly remains one of the biggest topics for Congress this week.
The Ethics Committee, which is evenly split between Democrats and Republicans, is expected to meet Wednesday to determine their next step in whether to release the report or not, the Wall Street Journal <a href="https://www.wsj.com/politics/policy/senators-want-details-on-sexual-misconduct-allegations-as-gaetz-seeks-fair-shake-7a1bfad7?mod=hp_lead_pos1">reported</a>.
The report would likely include the committee's findings into allegations that Gaetz had sexual relations with a 17-year-old minor. The former minor and another woman both said Gaetz paid them for sex, according to comments from their lawyer on Monday.
Gaetz denied allegations of having sex with a minor, sex trafficking or paying for sex previously.
Speaker of the House Mike Johnson (R-La.) said this week it would be a bad precedent if the committee releases the report with Gaetz no longer a member of Congress.
See Also: <a href="https://www.benzinga.com/politics/24/11/42077496/donald-trumps-personnel-picks-new-poll-finds-elon-musk-with-highest-approval-by-voters-matt-gaetz-with-highest-disapproval">Donald Trump&#8217;s Personnel Picks: New Poll Finds Elon Musk With Highest Approval By Voters, Matt Gaetz With Highest Disapproval</a>
Some members of Congress, including members of the Republican party, want to see the results of the committee ahead of a potential vote for Gaetz to be a member of Trump's cabinet.
"I'm saying to the people that want any cabinet person to get through — not just Gaetz — but it's going to be a lot faster if you give us all the information that we want," Sen. Chuck Grassley (R-Iowa) said.
The Ethics Committee previously planned to release their findings last week before Gaetz surprising resignation.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While The Republicans will have a majority of 53-47 when the new Congress term begins in January, four Republicans voting against any pick could see them fail to be approved through, assuming all Democrats vote against the candidate.
On Tuesday it was reported that an "unknown and unauthorized third party" gained access to depositions from witnesses in the Gaetz investigation, as <a href="https://www.cbsnews.com/news/matt-gaetz-depositions-leak-investigations/">reported </a>by CBS News.
The reported leak, which could include testimony from the minor who allegedly had sex with Gaetz, could put into question whether more details from the case will be released publicly, even if Congress doesn't do so.
On <a href="https://polymarket.com/event/who-will-be-trumps-attorney-general?tid=1732054162608">Polymarket</a>, the odds of Gaetz being approved as attorney general currently stand at 38%, up from <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say">28% four days ago. </a>The odds had previously hovered between 25% and 30%, before growing in recent days.
Gaetz has the best odds of any name listed in the Polymarket attorney general prediction market. On Polymarket, users can deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network, or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
Each betting market sees the winning option pay out at $1. Like the 2024 election markets, the odds of potential cabinet members are becoming hot betting markets on Polymarket.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Legal

$ETH

$MATIC

$USDC

USDC

Trump's Attorney General Pick Matt Gaetz Resigned From Congress, Ethics Committee To Decide If Report Will Be Released

President-elect Donald J. Trump <a href="https://www.benzinga.com/general/health-care/24/11/42077057/trump-picks-dr-oz-as-centers-for-medicare-and-medicaid-services-administrator">announced on Tuesday afternoon</a> that he will nominate TV personality Dr. Mehmet Oz to serve as the administrator of the Centers for <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks" target="_blank" rel="noreferrer noopener">Medicare and Medicaid Services (CMS)</a>. The appointment is among a string of TV hosts — mostly from Fox News — to be chosen to join Trump's cabinet.
In a statement, Trump said the celebrity TV host will "work closely with Robert F. Kennedy Jr. to take on the illness industrial complex."
Though a household name due to his long-running &#8220;The Dr. Oz Show" (2009-2022), Oz got into politics when he <a href="https://www.benzinga.com/markets/cannabis/22/06/27558526/dr-oz-to-face-john-fetterman-in-unprecedented-unpredictable-pa-senate-race-and-cannabis-is-on-th">unsuccessfully ran for Senate</a> against now Sen. John Fetterman (D-Penn.) in 2022, during which time the good doctor seemed to forge an alliance with Trump.
At the time, Scientific American&nbsp;<a href="https://www.scientificamerican.com/article/dr-oz-shouldnt-be-a-senator-or-a-doctor/" target="_blank" rel="noreferrer noopener">wrote </a>Dr. Oz should not&nbsp;be a senator or a doctor, noting that his misinformation had already tarnished medicine and would do much worse in the halls of Congress.&nbsp;"Dr. Oz&nbsp;has long pushed misleading, science-free and unproven alternative therapies such as homeopathy, as well as fad diets, detoxes and cleanses."
<h1 class="wp-block-heading">Donald Trump Begs To Differ</h1>
News outlets are quick to<a href="https://www.axios.com/2024/11/19/trump-dr-oz-cms-cabinet"> point out</a> that Dr. Oz has no experience running a large government body like the CMS but that seems to not matter because, according to the President-elect.
&#8220;There may be no Physician more qualified and capable than Dr. Oz to Make America Healthy Again,&#8221; Trump said in a statement, referring to the words of <a href="https://www.benzinga.com/topic/robert-f-kennedy-jr">Robert Kennedy Jr</a>. who will, if confirmed run the Dept. of Health and Human Services.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a>
<h1 class="wp-block-heading">Dr. Oz On Cannabis</h1>
The multimillionaire TV host initially called cannabis a &#8220;mixed bag for easing pain.&#8221; But a recent discussion with&nbsp;Michael Roizen,&nbsp;M.D., of the Wellness Institute at the Cleveland Clinic, Dr. <a href="https://www.benzinga.com/markets/cannabis/24/08/40492959/trump-endorsed-dr-oz-on-medical-marijuana-and-pain-give-it-a-try">Oz said</a>, &#8220;Our advice: If your physician recommends it to manage pain, especially if you&#8217;re 65 and older, give it a try.&#8221;
While Dr. Oz cautions against cannabis consumption for recreational purposes, he said he believes marijuana for pain represents a "safer solution than, for example, narcotics in many cases."
During his Senate race, Dr. Oz often criticized Fetterman&#8217;s support for cannabis legalization though several years earlier he himself <a href="https://www.marijuanamoment.net/dr-oz-claims-dea-and-fda-blame-each-other-for-keeping-marijuana-illegal/">referred to cannabis</a>&nbsp;as "one of the most underused tools in America" and that the U.S. should&nbsp;"completely change our policy on marijuana."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42069004/how-trumps-election-could-revolutionize-cannabis-and-cryptocurrency-ceo-says">How Trump&#8217;s Election Could Revolutionize Cannabis And Cryptocurrency, CEO Says</a></li>
</ul>

Cannabis

Health Care

Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services

AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) sees FY2025 sales of $1.510 billion-1.540 billion vs $1.43 billion estimate.

Guidance

AZEK

AZEK Co Sees FY2025 Sales $1.510B-1.540B vs $1.43B Est

Kore Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) raises FY2024 sales outlook from $275.00 million-285.00 million to $280.00 million-285.00 million.

KORE

Kore Group Holdings Raises FY2024 Sales Guidance from $275.00M-285.00M to $280.00M-285.00M

Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) is looking for Q1 Adj EPS of $(0.05)-0.10 vs $0.04 analyst estimate. sees sales of $195.000 million-215.000 million vs $189.43 million estimate.

VREX

Varex Imaging Sees Q1 Adj EPS $(0.05)-0.10 vs $0.04 Est; Sees Sales $195.000M-215.000M vs $189.43M Est

Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is looking for Q1 Adj EPS of $1.65-1.71 vs $1.57 analyst estimate. sees sales of $1.265 billion-1.285 billion vs $1.26 billion estimate.

KEYS

Keysight Techs Sees Q1 Adj EPS $1.65-1.71 vs $1.57 Est; Sees Sales $1.265B-1.285B vs $1.26B Est

Concentra Group To Replace Myers Industries In S&P SmallCap 600 Effective Prior To Opening Of Trading On November 27

AZTA

Azenta To Replace Envestnet In S&P SmallCap 600 Effective Prior To The Opening Of Trading On November 25

FLEX

Flex To Replace Azenta In S&P MidCap 400

Donald Trump has announced several picks for potential nominees for his White House administration since winning the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">2024 presidential election.</a>
While the picks still have to be nominated and approved in many cases, voters were recently asked to share whether they approve of or disapprove of his current selections.
What Happened: Trump's announced picks have generated plenty of discussion on social media and across the political spectrum with the announced picks of Matt Gaetz <a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation">as attorney general</a> and Robert F. Kennedy Jr. leading the Health and Human Services generating the most buzz.
A new Morning Consult <a href="https://pro.morningconsult.com/analysis/trump-transition-nominees-approval">poll </a>asked voters how they think Trump is doing with his transition.
The poll found that 54% of voters approve of Trump's handling of his transition since winning the 2024 election, with 38% disapproving and 8% saying they don't know or had no opinion.
Split by political party, Republicans showed a higher approval rating (93%) of Trump's handling of the transition compared to Democrats (20%). Independent voters were more split with 46% approving, 40% disapproving and 14% having no opinion or saying they don't know.
Trump's 54% approval rating is only six points below the 60% approval rating President Joe Biden had four years ago from a Morning Consult poll.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Personnel Pick Ratings: Here are the approval and disapproval ratings of recent personnel picks by Trump for his next White House term.
<ul>
<li>Mike Huckabee, U.S. Ambassador to Israel: 44% approval, 31% disapproval, 25% no opinion</li>
<li>Marco Rubio, Secretary of State: 45% approval, 34% disapproval, 21% no opinion</li>
<li>Elise Stefanik, U.S. Ambassador to the United Nations: 38% approval, 29% disapproval, 33% no opinion</li>
<li>Stephen Miller, Deputy White House Chief of Staff: 36% approval, 30% disapproval, 34% no opinion</li>
<li>Tulsi Gabbard, Director of National Intelligence: 39% approval, 33% disapproval, 29% no opinion</li>
<li>Robert F. Kennedy Jr., Health and Human Services Secretary: 44% approval, 39% disapproval, 16% no opinion</li>
<li>Elon Musk, co-leader of the Department of Government Efficiency: 45% approval, 40% disapproval, 15% no opinion</li>
<li>Vivek Ramaswamy, co-leader of the Department of Government Efficiency: 39% approval, 34% disapproval, 27% no opinion</li>
<li>Lee Zeldin, Environmental Protection Agency Administration: 34% approval, 29% disapproval, 37% no opinion</li>
<li>Pete Hegseth, Secretary of Defense: 37% approval, 32% disapproval, 31% no opinion</li>
<li>Kristi Noem, Secretary of Homeland Security: 37% approval, 33% disapproval, 30% no opinion</li>
<li>Matt Gaetz, Attorney General: 34% approval, 41% disapproval, 25% no opinion</li>
</ul>
Why It's Important: The selection of Gaetz could face the most scrutiny by members of Congress if he is formally nominated. The Republican resigned from Congress the same day Trump announced the attorney general role for him.
Gaetz was investigated by the Department of Justice for sex trafficking before it declined to charge the congressman.
The former Congressman was under investigation by the House Ethics Committee for sexual misconduct. Allegations against the Trump ally include sexual misconduct, illicit drug use, accepting improper gifts and more. Gaetz has denied the allegations.
Gaetz is the only person in the poll to receive a higher percentage of disapproval than approval.
When it comes to disapproval, Gaetz ranks first at 41% followed by Tesla CEO Elon Musk at 40%.
Musk, who has been named by Trump to lead the Department of Government Efficiency and cut government spending, also has the <a href="https://www.benzinga.com/politics/24/11/41993300/elon-musks-favorability-with-gop-voters-nearly-as-high-as-j-d-vance-how-views-of-billionaire-changed-among-political-parties">highest approval rating</a> at 45%, tied with Marco Rubio.
Musk has the lowest percent of voters saying no opinion, showing how opinionated voters are of his potential selection. Musk maintains a positive net approval rating of 45% to a disapproval rating of 40%.
Kennedy Jr. ranks among the highest for approval at 44% and for disapproval at 39%. Like Musk, Kennedy also has a low amount of voters saying they have no opinion at 16%.
Huckabee has the highest net approval rating in the poll at 13 points.
This poll was taken before Trump announced Dr. Mehmet Oz as his choice as <a href="https://www.benzinga.com/general/health-care/24/11/42077057/trump-picks-dr-oz-as-centers-for-medicare-and-medicaid-services-administrator">Centers For Medicare and Medicaid Services administrator</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a></li>
</ul>
Photo: Musk, White House, public domain; Trump and Getz, Shutterstock

Donald Trump's Personnel Picks: New Poll Finds Elon Musk With Highest Approval By Voters, Matt Gaetz With Highest Disapproval

Telsey Advisory Group analyst Joseph Feldman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $92 to $100.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Walmart, Raises Price Target to $100

ZTO Cuts 2024 Outlook For Parcel Volume From 34.73B - 35.64B To 33.7B - 33.9B Based On Current Market And Operating Conditions

KITT

Nauticus Robotics Enters Strategic Collaboration With SeaTrepid To Integrate And Test Its ToolKITT Software On Remotely Operated Vehicles

Canaccord Genuity analyst Caitlin Cronin maintains Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) with a Buy and maintains $60 price target.

VCEL

Canaccord Genuity Maintains Buy on Vericel, Maintains $60 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!



Moving stocks this morning are earnings reports, an acquisition deal, a delisting notice and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Tevogen Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tvgn-stock-quote/">TVGN</a>) stock is rocketing more than 71% after announcing <a href="https://www.nasdaq.com/press-release/tevogen-bio-announces-up-to-%2450-million-in-financing-to-further-advance-operational">$50 million in additional financing</a>.</li>



<li>AC Immune (NASDAQ:<a href="https://investorplace.com/stock-quotes/aciu-stock-quote/">ACIU</a>) shares are soaring over 48% alongside its <a href="https://www.nasdaq.com/press-release/ac-immune-reports-first-quarter-2024-financial-results-and-provides-a-corporate">Q1 2024 earnings report</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) stock is surging more than 31% with heavy pre-market trading.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) shares are gaining over 21% without any clear news this morning.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) stock is rising more than 19% with the <a href="https://www.marketwatch.com/story/roaring-kitty-is-back-and-gamestop-stock-is-rallying-the-company-still-is-struggling-to-make-money-ca4607c3">return of Roaring Kitty</a>.</li>



<li>XTL Biopharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/">XTLB</a>) shares are increasing over 19% despite a lack of news today.</li>



<li>JanOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/jan-stock-quote/">JAN</a>) stock is climbing more than 16% on plans to <a href="https://www.prnewswire.com/news-releases/janone-to-acquire-alt-5-sigma-inc-a-leading-next-generation-blockchain-financial-technology-provider-302142674.html">acquire Alt 5 Sigma</a>.</li>



<li>Fulcrum Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/fulc-stock-quote/">FULC</a>) shares are climbing over 16% on <a href="https://www.nasdaq.com/press-release/fulcrum-therapeutics-enters-into-a-collaboration-and-license-agreement-with-sanofi">a collaboration agreement</a> with Sanofi&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sny-stock-quote/">SNY</a>)</li>



<li>Plutonian Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/pltn-stock-quote/">PLTN</a>) stock is jumping more than 15% this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares are up over 14% on Monday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>AEye (NASDAQ:<a href="https://investorplace.com/stock-quotes/lidr-stock-quote/">LIDR</a>) stock is diving close to 14% <a href="https://investorplace.com/2024/05/why-is-aeye-lidr-stock-up-38-today/">following a Friday rally</a>.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) shares are tumbling about 13% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318311138&amp;type=PDF&amp;symbol=SGD&amp;cdn=507b0bfaecfda3ee7d6769c0869f5747&amp;companyName=Safe+and+Green+Development+Corporation&amp;formType=D&amp;formDescription=Notice+of+Exempt+Offering+of+Securities&amp;dateFiled=2024-05-10">Notice of Exempt Offering of Securities</a> filing to the Securities and Exchange Commission (SEC).</li>



<li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is taking a more than 12% beating alongside plans for its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318310991&amp;type=PDF&amp;symbol=RNAZ&amp;cdn=43164c7cc1aa0080fb04a692a6a78bd2&amp;companyName=TransCode+Therapeutics+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-05-10">annual shareholder meeting</a>.</li>



<li>Visionary (NASDAQ:<a href="https://investorplace.com/stock-quotes/gv-stock-quote/">GV</a>) shares are sliding over 11% following a similar rally on the prior trading day.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is dropping more than 11% without any apparent news this morning.</li>



<li>Power REIT (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pw-stock-quote/">PW</a>) shares are falling over 10% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318310902&amp;type=PDF&amp;symbol=PW&amp;cdn=11f58b2db1a9e1bae7887bdcbd213c86&amp;companyName=Power+REIT+%28MD%29&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-05-10">rallying Friday on earnings</a>.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is decreasing more than 10% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318311286&amp;type=PDF&amp;symbol=CYN&amp;cdn=ed67470a33a490d78ff90c97e3b68660&amp;companyName=Cyngn+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-05-10">shareholder meeting plans</a>.</li>



<li>Vitesse Energy (NYSE:<a href="https://investorplace.com/stock-quotes/vts-stock-quote/">VTS</a>) shares are slipping over 10% on Monday.</li>



<li>AYRO (NASDAQ:<a href="https://investorplace.com/stock-quotes/ayro-stock-quote/">AYRO</a>) stock is dipping more than 9% this morning.</li>



<li>Heart Test Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) shares close out our pre-market stock movers down over 9% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318310504&amp;type=PDF&amp;symbol=HSCS&amp;cdn=520cd089afcc06b6a1b1e5f350c05d40&amp;companyName=Heart+Test+Laboratories+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-10">with a delisting notice</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-may-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers

Heart Test conducts 1-for-100 reverse stock split

OGEN, BWEN and SINT among mid-day movers

Heart Test Laboratories regains compliance with Nasdaq listing requirements

Heart Test Laboratories reports FY results

Heart Test Laboratories GAAP EPS of -$2.64 misses by $0.18

Allen Klee, an analyst from Maxim Group, reiterated the Buy rating on Heart Test Laboratories, Inc. (HSCS – Research Report). The associated price ...

Buy Rating Justified by Heart Test Laboratories' Strong R&D and Solid Financial Footing

Seelos Therapeutics, Heart Test Laboratories, and XChange TEC are the 3 Penny Stocks to watch on September 25, 2024, based on&nbsp;TipRanks' Penny ...

3 Penny Stocks to Watch Now, 9/25/24

Heart Test Laboratories (HSCS) announced that the Centers for Medicare & Medicaid Services, CMS, has included AI-ECG technology in the 2025 Hospita...

Heart Test announces CMS included AI-ECG tech in 2025 OPPS final rule

ACIU

AKAN

AMPG

ARQT

AYRO

BBLG

BCAN

BTTR

BURU

BWEN

CAPR

DRMA

DYNT

EDBL

FULC

HSCS

JDZG

LIDR

LSDI

NEPH

NTBL

NVAX

OGEN

PEGY

PLTN

RCRT

RENT

RNAZ

SEEL

SGBX

SINT

TVGN

XTLB

Markets

Press Releases

HeartSciences Regains Compliance with Nasdaq Listing Requirements

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

General

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Financing

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential"

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Comments

HeartSciences

HeartSciences (HSCS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL